0001209191-22-001241.txt : 20220104 0001209191-22-001241.hdr.sgml : 20220104 20220104210923 ACCESSION NUMBER: 0001209191-22-001241 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220104 DATE AS OF CHANGE: 20220104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lin Elizabeth Yeu CENTRAL INDEX KEY: 0001842190 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39614 FILM NUMBER: 22508692 MAIL ADDRESS: STREET 1: 25651 ATLANTIC OCEAN DRIVE CITY: LAKE FOREST STATE: CA ZIP: 92630 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001819790 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 814717861 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: (949) 409-9820 MAIL ADDRESS: STREET 1: 15440 LAGUNA CANYON ROAD CITY: IRVINE STATE: CA ZIP: 92618 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-12-31 0 0001819790 Tarsus Pharmaceuticals, Inc. TARS 0001842190 Lin Elizabeth Yeu C/O TARSUS PHARMACEUTICALS, INC. 15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE CA 92618 1 0 0 0 Employee Stock Option (right to buy) 2.01 2030-05-13 Common Stock 2019 D Employee Stock Option (right to buy) 10.99 2030-09-24 Common Stock 33372 D Employee Stock Option (right to buy) 10.99 2030-09-24 Common Stock 4543 D Employee Stock Option (right to buy) 34.72 2031-03-01 Common Stock 5200 D Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). 504 of the option shares vest and become exercisable on April 16, 2021. The remainder of the option shares vest and become exercisable in 36 equal monthly installments beginning May 16, 2021. Option granted under the Plan. The option shares vest and become exercisable in 48 equal monthly installments beginning on September 1, 2020. Option granted under the Plan. The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020. Option granted under the Plan. The option shares vest and become exercisable on March 2, 2022. Exhibit 24 - Power of Attorney /s/ Leonard M. Greenstein, Attorney-in-Fact 2022-01-04 EX-24 2 attachment1.htm EX-24 DOCUMENT

Tarsus Pharmaceuticals, Inc. - Power of Attorney

KNOW ALL BY THESE PRESENTS, the undersigned hereby constitutes and appoints each
of Bobak Azamian, Leonard Greenstein, Bryan Wahl, Kim Norman, and Shannon
Callan, signing singly, and with full power of substitution, the undersigned's
true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned a Form ID Application, if
required, and submit the same to the United States Securities and Exchange
Commission;

(2) execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director of Tarsus Pharmaceuticals, Inc. (the "Company") or
as a holder of 10% or more of the Company's securities, Forms 3, 4 and 5, and
any amendments thereto, in accordance with Section 16 of the Securities Exchange
Act of 1934, as amended, and the rules thereunder and, if necessary, such forms
or similar reports required by state or foreign regulators in jurisdictions in
which the Company operates;

(3) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute any such Form 3, 4 or 5 or
similar form or report required by state or foreign regulators, and any
amendments thereto, and file such form or report with the United States
Securities and Exchange Commission and any stock exchange or similar authority
or appropriate state or foreign regulator; and

(4) take any other action of any type whatsoever in connection with the
foregoing that, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of or legally required to be done by the undersigned, it
being understood that the documents executed by such attorney-in-fact on behalf
of the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended, and the
rules thereunder. This Power of Attorney may be filed with the SEC as a
confirming statement of the authority granted herein.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of the date written below.

Date: December 31, 2021
By: /s/ Elizabeth Yeu-Lin
Name: Elizabeth Yeu-Lin